| Literature DB >> 23690864 |
Taro Tomura1, Kouichi Yoshimasu, Jin Fukumoto, Shigeki Takemura, Shunji Sakaguchi, Nobuyuki Miyai, Kazuhisa Miyashita.
Abstract
In acupuncture therapy, diagnosis, acupoints, and stimulation for patients with the same illness are often inconsistent among between Traditional Chinese Medicine (TCM) practitioners. This is in part due to the paucity of evidence-based diagnostic methods in TCM. To solve this problem, establishment of validated diagnostic tool is inevitable. We first applied the Item Response Theory (IRT) model to the Five Viscera Score (FVS) to test its validity by evaluating the ability of the questionnaire items to identify an individual's latent traits. Next, the health-related QOL scale (SF-36), a suitable instrument for evaluating acupuncture therapy, was administered to evaluate whether the FVS can be used to make a health-related diagnosis. All 20 items of the FVS had adequate item discrimination, and 13 items had high item discrimination power. Measurement accuracy was suited for application in a range of individuals, from healthy to symptomatic. When the FVS and SF-36 were administered to other subjects, a part of which overlap with the first subjects, we found an association between the two scales, and the same findings were obtained when symptomatic and asymptomatic subjects were compared regardless of age and sex. In conclusion, the FVS may be effective in clinical diagnosis.Entities:
Year: 2013 PMID: 23690864 PMCID: PMC3638591 DOI: 10.1155/2013/928089
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Item discrimination and difficulty of the Five Viscera Score by Item Response Theory. (n = 594).
| Subscale | Item number | Item |
| Mean |
|
|
|
| Factor loading | Cronbach's | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver | 0.77 | ||||||||||||||
| Q1 | I have a stiff neck | 2.11 (0.11) | 0.11 | −0.76 (0.10) | −0.22 (0.07) | 0.35 (0.08) | 1.07 (0.13) | 0.82 | |||||||
| Q2 | I have a pulled muscle in my neck | 2.57 (0.14) | 0.55 | −0.14 (0.08) | 0.25 (0.08) | 0.76 (0.13) | 1.35 (0.20) | 0.81 | |||||||
| Q3 | I have a backache | 0.77 (0.06) | 1.40 | −0.17 (0.05) | 0.71 (0.06) | 2.12 (0.09) | 2.94 (0.14) | 0.49 | |||||||
| Q4 | I have migraine headaches (headaches) | 0.58 (0.05) | 2.40 | −0.26 (0.05) | 1.10 (0.06) | 3.46 (0.12) | 5.32 (0.27) | 0.41 | |||||||
| Heart | 0.82 | ||||||||||||||
| Q5 | I worry about many things | 2.40 (0.12) | 0.40 | −0.66 (0.10) | 0.09 (0.08) | 0.82 (0.12) | 1.35 (0.18) | 0.83 | |||||||
| Q6 | I worry frequently | 1.84 (0.10) | 0.50 | −0.63 (0.09) | 0.23 (0.07) | 0.96 (0.11) | 1.46 (0.15) | 0.76 | |||||||
| Q7 | I have a lot on my mind and am not able to enjoy anything | 1.09 (0.07) | 1.19 | −0.38 (0.06) | 0.76 (0.07) | 1.86 (0.11) | 2.54 (0.16) | 0.57 | |||||||
| Q8 | I sigh often | 0.80 (0.06) | 0.89 | −0.85 (0.06) | 0.36 (0.06) | 1.68 (0.08) | 2.37 (0.11) | 0.39 | |||||||
| Spleen | 0.82 | ||||||||||||||
| Q9 | I am fatigued and this is not alleviated by anything | 1.76 (0.09) | 0.25 | −1.14 (0.11) | −0.09 (0.07) | 0.72 (0.09) | 1.50 (0.14) | 0.69 | |||||||
| Q10 | I have to lie down due to fatigue | 0.93 (0.06) | 0.61 | −1.24 (0.07) | 0.02 (0.06) | 1.37 (0.08) | 2.32 (0.12) | 0.60 | |||||||
| Q11 | My body feels heavy | 1.62 (0.08) | 0.33 | −0.90 (0.09) | −0.11 (0.07) | 0.83 (0.09) | 1.52 (0.13) | 0.55 | |||||||
| Q12 | I don't have much energy in the morning | 1.12 (0.07) | 0.83 | −0.50 (0.06) | 0.46 (0.06) | 1.33 (0.09) | 2.02 (0.12) | 0.47 | |||||||
| Lung | 0.64 | ||||||||||||||
| Q13 | My stomach rumbles | 1.45 (0.08) | 0.70 | −0.88 (0.09) | 0.03 (0.06) | 1.46 (0.12) | 2.21 (0.18) | 0.74 | |||||||
| Q14 | I feel hungry constantly | 1.01 (0.07) | 1.29 | −0.43 (0.06) | 0.77 (0.07) | 1.96 (0.11) | 2.85 (0.18) | 0.58 | |||||||
| Q15 | I have a runny nose | 0.61 (0.05) | 1.30 | −1.25 (0.06) | 0.32 (0.05) | 2.34 (0.08) | 3.79 (0.15) | 0.41 | |||||||
| Q16 | I get the hiccups | 0.48 (0.05) | 3.85 | −0.09 (0.05) | 2.24 (0.07) | 5.95 (0.24) | 7.30 (0.41) | 0.36 | |||||||
| Kidney | 0.79 | ||||||||||||||
| Q17 | I am absent minded | 1.70 (0.09) | 0.80 | −0.48 (0.08) | 0.38 (0.07) | 1.25 (0.12) | 2.06 (0.20) | 0.58 | |||||||
| Q18 | I am not energetic | 1.45 (0.08) | 0.98 | −0.42 (0.07) | 0.63 (0.08) | 1.59 (0.13) | 2.12 (0.17) | 0.53 | |||||||
| Q19 | My memory has deteriorated | 1.01 (0.07) | 1.03 | −0.34 (0.06) | 0.61 (0.06) | 1.60 (0.09) | 2.25 (0.13) | 0.49 | |||||||
| Q20 | I feel lethargic to the point where I have to lie down | 0.96 (0.06) | 0.81 | −0.58 (0.06) | 0.39 (0.06) | 1.43 (0.08) | 2.00 (0.11) | 0.43 | |||||||
FVS: Five Viscera Score, a: item discrimination, b: item difficulty (), b1: point of intersection with curve 1 and curve 2, b2: point of intersection with curve 2 and curve 3, b3: point of intersection with curve 3 and curve 4, b4: point of intersection with curve 4 and curve 5, and SE: standard error. Mean b is the average of 4 item difficulty values. Item discrimination represents the ability of an item to differentiate the subjects. Overall Cronbach's α 0.91.
Figure 1Graphic representation of Q1 of the Five Viscera Score by Item Response Theory. It shows a chart for understanding item discrimination and item difficulty of IRT. The slope of the curves represents item discrimination, and in the point of intersection of the curves represents item difficulty.
Characteristics of respondents, Phase 1.
| Sociodemographic characteristics | Male ( | Female ( |
|---|---|---|
|
|
| |
| Age (y) | ||
| 18-19 | 55 (12.8) | 39 (23.8) |
| 20–29 | 240 (55.8) | 82 (50.0) |
| 30–39 | 102 (23.7) | 28 (17.1) |
| 40–49 | 24 (5.6) | 12 (7.3) |
| 50+ | 9 (2.1) | 3 (1.8) |
| Mean (SD) | 27.5 (8.0) | 26.0 (8.5) |
| Education | ||
| Junior college or lower | 274 (63.7) | 101 (61.6) |
| College or higher | 141 (32.8) | 57 (34.8) |
| Unknown | 15 (3.5) | 6 (3.7) |
| Work 4 days or more per week during last month | ||
| No | 96 (22.3) | 79 (48.2) |
| Yes | 334 (77.7) | 85 (51.8) |
Figure 2Test information curves of the Five Viscera Score. It shows the quantity of measurement information from the subscales resulting from the application of IRT. The subscales are expected to be applied to those who are in that range. All the effective ability ranges straddled zero and extended in the positive direction.
Correlation in male and female of the Five Viscera Score and SF-36.
| Generation | Subscale | Whole ( | Male ( | Female ( | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver | Heart | Spleen | Lung | Kidney | Liver | Heart | Spleen | Lung | Kidney | Liver | Heart | Spleen | Lung | Kidney | ||
| PF | −0.20*** | −0.23*** | −0.28*** | −0.03 | −0.28*** | −0.20** | −0.21** | −0.30*** | 0.00 | −0.32*** | −0.18 | −0.26** | −0.25* | −0.07 | −0.18 | |
| RP | −0.11 | −0.37*** | −0.30*** | −0.06 | −0.31*** | −0.11 | −0.39*** | −0.28*** | −0.11 | −0.34*** | −0.06 | −0.34*** | −0.35*** | 0.03 | −0.24* | |
| BP | −0.40*** | −0.35*** | −0.41*** | −0.21*** | −0.32*** | −0.38*** | −0.31*** | −0.42*** | −0.22** | −0.30*** | −0.36*** | −0.38*** | −0.38*** | −0.19 | −0.27** | |
| Whole subjects | GH | −0.36*** | −0.49*** | −0.44*** | −0.15* | −0.39*** | −0.33*** | −0.46*** | −0.40*** | −0.22** | −0.39*** | −0.45*** | −0.56*** | −0.53*** | −0.02 | −0.39*** |
| VT | −0.33*** | −0.57*** | −0.59*** | −0.07 | −0.56*** | −0.31*** | −0.53*** | −0.59*** | −0.09 | −0.55*** | −0.34*** | −0.63*** | −0.61*** | −0.05 | −0.54*** | |
| SF | −0.17** | −0.41*** | −0.37*** | −0.25*** | −0.45*** | −0.15 | −0.36*** | −0.32*** | −0.26*** | −0.40*** | −0.18 | −0.47*** | −0.45*** | −0.22* | −0.50*** | |
| RE | −0.11 | −0.46*** | −0.36*** | −0.13* | −0.42*** | −0.11 | −0.46*** | −0.33*** | −0.17* | −0.41*** | −0.07 | −0.46*** | −0.40*** | −0.06 | −0.41*** | |
| MH | −0.33*** | −0.74*** | −0.46*** | −0.16** | −0.54*** | −0.30*** | −0.76*** | −0.43*** | −0.14 | −0.53*** | −0.33*** | −0.70*** | −0.49*** | −0.20 | −0.53*** | |
|
| ||||||||||||||||
| PF | −0.23** | −0.25*** | −0.27*** | 0.04 | −0.26*** | −0.25** | −0.23* | −0.27** | 0.10 | −0.25** | −0.19 | −0.31* | −0.26* | −0.08 | −0.25* | |
| RP | −0.10 | −0.31*** | −0.26*** | −0.01 | −0.28*** | −0.12 | −0.29** | −0.16 | −0.04 | −0.24* | −0.04 | −0.34** | −0.42*** | 0.03 | −0.32* | |
| BP | −0.40*** | −0.38*** | −0.33*** | −0.25*** | −0.28*** | −0.39*** | −0.36*** | −0.34*** | −0.24* | −0.25** | −0.34** | −0.38** | −0.27* | −0.27* | −0.25* | |
| Adolescents and young adults (18–29) | GH | −0.42*** | −0.50*** | −0.39*** | −0.16* | −0.36*** | −0.38*** | −0.50*** | −0.38*** | −0.24* | −0.37*** | −0.51*** | −0.50*** | −0.41*** | −0.03 | −0.37** |
| VT | −0.31*** | −0.54*** | −0.53*** | 0.00 | −0.53*** | −0.30** | −0.49*** | −0.53*** | 0.04 | −0.51*** | −0.33** | −0.61*** | −0.54*** | −0.07 | −0.58*** | |
| SF | −0.19* | −0.42*** | −0.33*** | −0.22** | −0.46*** | −0.18 | −0.38*** | −0.30** | −0.18 | −0.37*** | −0.19 | −0.47*** | −0.38** | −0.27* | −0.59*** | |
| RE | −0.16* | −0.43*** | −0.41*** | −0.08 | −0.42*** | −0.13 | −0.40*** | −0.30** | −0.06 | −0.37*** | −0.15 | −0.46*** | −0.56*** | −0.08 | −0.49*** | |
| MH | −0.36*** | −0.72*** | −0.40*** | −0.11 | −0.53*** | −0.32*** | −0.72*** | −0.36*** | −0.02 | −0.49*** | −0.40*** | −0.73*** | −0.48*** | −0.24 | −0.60*** | |
|
| ||||||||||||||||
| PF | −0.14 | −0.21* | −0.31** | −0.17 | −0.33*** | −0.11 | −0.15 | −0.34** | −0.18 | −0.42*** | −0.09 | −0.25 | −0.31 | −0.19 | −0.14 | |
| RP | −0.11 | −0.45*** | −0.35*** | −0.13 | −0.37*** | −0.10 | −0.50*** | −0.46*** | −0.18 | −0.53*** | −0.05 | −0.33 | −0.24 | 0.00 | −0.11 | |
| BP | −0.40*** | −0.30** | −0.55*** | −0.15 | −0.39*** | −0.37** | −0.20 | −0.55*** | −0.17 | −0.38** | −0.38* | −0.39* | −0.58*** | −0.10 | −0.34* | |
| Adults (30+) | GH | −0.27** | −0.46*** | −0.50*** | −0.14 | −0.44*** | −0.25* | −0.34** | −0.41*** | −0.16 | −0.44*** | −0.30 | −0.68*** | −0.72*** | −0.07 | −0.41* |
| VT | −0.35*** | −0.64*** | −0.68*** | −0.15 | −0.59*** | −0.33** | −0.61*** | −0.69*** | −0.21 | −0.66*** | −0.37* | −0.71*** | −0.75*** | −0.07 | −0.48** | |
| SF | −0.12 | −0.36*** | −0.40*** | −0.27** | −0.43*** | −0.10 | −0.29* | −0.33** | −0.37** | −0.48*** | −0.16 | −0.47** | −0.55*** | −0.06 | −0.34* | |
| RE | −0.05 | −0.50*** | −0.27** | −0.19 | −0.42*** | −0.08 | −0.47*** | −0.35** | −0.30* | −0.51*** | 0.10 | −0.44** | −0.07 | 0.06 | −0.25 | |
| MH | −0.27** | −0.78*** | −0.56*** | −0.26** | −0.56*** | −0.27* | −0.81*** | −0.57*** | −0.32* | −0.62*** | −0.17 | −0.70*** | −0.55*** | −0.11 | −0.39* | |
*P < 0.05; **P < 0.01; ***P < 0.001 (r; Spearman's rank correlation coefficient); PF: physical functioning; RP: role physical; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role emotional; MH: mental health. Whole (n = 274; male n = 175; female n = 99), adolescents/young adults (n = 174; male n = 110; female n = 64), and adults (n = 100; male n = 65; female n = 35).
Comparison by the presence of the symptom of the Five Viscera Score and SF-36.
| Whole | Male | Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Scale name | Subscale | Health condition | Health condition | Health condition | ||||||
| Good ( | Poor ( |
| Good ( | Poor ( |
| Good ( | Poor ( |
| ||
| Liver | 6.57 (3.56) | 8.48 (3.62) | 0.016 | 6.31 (3.62) | 7.23 (3.96) | 0.474 | 7.07 (3.40) | 9.83 (2.76) | 0.006 | |
| Heart | 6.73 (3.82) | 8.96 (4.29) | 0.018 | 6.56 (3.89) | 7.77 (4.68) | 0.472 | 7.06 (3.67) | 10.25 (3.57) | 0.010 | |
| FVS | Spleen | 7.61 (3.67) | 9.84 (4.18) | 0.015 | 7.55 (3.60) | 9.23 (4.68) | 0.276 | 7.72 (3.82) | 10.50 (3.66) | 0.028 |
| Lung | 5.00 (2.47) | 5.88 (3.68) | 0.349 | 5.02 (2.55) | 5.62 (3.55) | 0.634 | 4.97 (2.33) | 6.17 (3.95) | 0.414 | |
| Kidney | 6.24 (3.21) | 7.96 (3.95) | 0.040 | 5.96 (3.19) | 7.46 (4.16) | 0.268 | 6.76 (3.21) | 8.50 (3.83) | 0.111 | |
|
| ||||||||||
| PF | 51.99 (7.71) | 49.15 (11.92) | 0.480 | 52.08 (7.84) | 49.75 (14.45) | 0.781 | 51.83 (7.48) | 48.50 (9.01) | 0.189 | |
| RP | 46.68 (12.08) | 44.42 (9.91) | 0.131 | 47.49 (11.72) | 44.98 (10.94) | 0.296 | 45.17 (12.66) | 43.82 (9.12) | 0.368 | |
| BP | 47.83 (10.29) | 40.96 (11.65) | 0.005 | 49.71 (9.79) | 43.51 (11.74) | 0.061 | 44.32 (10.33) | 38.20 (11.39) | 0.081 | |
| SF-36 | GH | 51.05 (10.57) | 39.61 (9.82) | 0.000 | 50.93 (10.94) | 40.55 (10.60) | 0.001 | 51.26 (9.90) | 38.59 (9.25) | <0.001 |
| VT | 43.67 (10.17) | 37.15 (13.52) | 0.029 | 44.36 (10.18) | 39.94 (11.07) | 0.233 | 42.38 (10.09) | 34.13 (15.69) | 0.068 | |
| SF | 48.29 (11.47) | 41.28 (16.11) | 0.038 | 49.17 (10.81) | 44.62 (16.72) | 0.533 | 46.64 (12.52) | 37.67 (15.30) | 0.036 | |
| RE | 46.86 (11.85) | 41.93 (14.68) | 0.101 | 48.30 (11.24) | 43.60 (12.95) | 0.154 | 44.17 (12.53) | 40.12 (16.75) | 0.523 | |
| MH | 44.67 (10.36) | 36.15 (14.41) | 0.008 | 45.30 (10.25) | 41.08 (14.29) | 0.455 | 43.49 (10.52) | 30.80 (13.06) | 0.003 | |
FVS: Five Viscera Score; mean (SD); SD: standard deviation; PF: physical functioning; RP: role physical; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role emotional; MH: mental health; †Mann-Whitney U test. Poor: subjects who responded “always” or “most of the time” to the questionnaire items “seeing a doctor for an illness” and “taking medication for an illness”; good: the others excluding “poor.”
Gender differences and the correlation of a raw scale score and the latent trait θ.
| Raw score | Latent trait | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Generation | Subscale | Male | Female |
| Male | Female |
| Male | Female | Whole | ||||||||
|
| Mean | (SD) |
| Mean | (SD) |
| Mean | (SD) |
| Mean | (SD) | |||||||
|
| Liver | 430 | 4.45 | (3.62) | 164 | 6.67 | (3.95) | <0.001 | 421 | 0.11 | (0.85) | 164 | 0.53 | (1.07) | <0.001 | 0.77*** | 0.92*** | 0.83*** |
|
| Heart | 430 | 5.00 | (3.89) | 164 | 5.98 | (3.75) | 0.002 | 418 | 0.12 | (0.81) | 163 | 0.26 | (0.88) | 0.038 | 0.79*** | 0.92*** | 0.83*** |
| Whole subjects | Spleen | 430 | 5.82 | (3.82) | 164 | 6.89 | (3.81) | 0.001 | 414 | 0.04 | (0.92) | 160 | 0.28 | (0.87) | 0.001 | 0.91*** | 0.94*** | 0.92*** |
|
| Lung | 430 | 4.24 | (2.64) | 164 | 5.04 | (2.75) | 0.002 | 405 | 0.11 | (0.98) | 158 | 0.44 | (0.98) | <0.001 | 0.87*** | 0.93*** | 0.89*** |
|
| Kidney | 430 | 4.31 | (3.59) | 164 | 5.71 | (3.68) | <0.001 | 356 | 0.17 | (0.84) | 153 | 0.41 | (0.87) | 0.003 | 0.95*** | 0.97*** | 0.96*** |
|
| ||||||||||||||||||
|
| Liver | 295 | 4.27 | (3.63) | 121 | 6.21 | (3.88) | <0.001 | 290 | 0.08 | (0.86) | 121 | 0.34 | (1.01) | 0.013 | 0.73*** | 0.91*** | 0.80*** |
|
| Heart | 295 | 4.94 | (3.85) | 121 | 6.17 | (3.82) | 0.001 | 287 | 0.11 | (0.81) | 121 | 0.31 | (0.89) | 0.015 | 0.78*** | 0.91*** | 0.83*** |
| Adolescents and young adults (18–29) | Spleen | 295 | 5.83 | (3.96) | 121 | 6.93 | (3.89) | 0.005 | 284 | 0.02 | (0.95) | 119 | 0.25 | (0.91) | 0.008 | 0.90*** | 0.94*** | 0.91*** |
|
| Lung | 295 | 4.40 | (2.72) | 121 | 5.25 | (2.75) | 0.004 | 279 | 0.15 | (1.02) | 118 | 0.52 | (0.94) | <0.001 | 0.87*** | 0.93*** | 0.90*** |
|
| Kidney | 295 | 4.24 | (3.61) | 121 | 5.63 | (3.69) | <0.001 | 243 | 0.17 | (0.85) | 114 | 0.38 | (0.87) | 0.023 | 0.95*** | 0.97*** | 0.96*** |
|
| ||||||||||||||||||
|
| Liver | 135 | 4.84 | (3.57) | 43 | 7.98 | (3.88) | <0.001 | 131 | 0.17 | (0.85) | 43 | 1.06 | (1.08) | <0.001 | 0.86*** | 0.97*** | 0.91*** |
|
| Heart | 135 | 5.13 | (3.98) | 43 | 5.44 | (3.54) | 0.533 | 131 | 0.13 | (0.81) | 42 | 0.09 | (0.86) | 0.850 | 0.82*** | 0.97*** | 0.86*** |
| Adults (30+) | Spleen | 135 | 5.79 | (3.51) | 43 | 6.77 | (3.61) | 0.089 | 130 | 0.08 | (0.84) | 41 | 0.36 | (0.76) | 0.042 | 0.94*** | 0.96*** | 0.95*** |
|
| Lung | 135 | 3.90 | (2.44) | 43 | 4.44 | (2.71) | 0.326 | 126 | 0.04 | (0.87) | 40 | 0.22 | (1.09) | 0.489 | 0.87*** | 0.92*** | 0.89*** |
|
| Kidney | 135 | 4.47 | (3.55) | 43 | 5.93 | (3.69) | 0.017 | 113 | 0.17 | (0.81) | 39 | 0.50 | (0.88) | 0.039 | 0.96*** | 0.97*** | 0.96*** |
***P< 0.001, r: Spearman's rank correlation coefficient, †Mann-Whitney U test, ††due to marginal maximum likelihood estimation, and cannot be determined for scores that are either 0 or 16.